Benzinga | Nov 10, 2021 04:07PM EST

Navidea Biopharmaceutical Q3 EPS $(0.08) Beats $(0.11) Estimate, Sales $96.00K Down From $268.39K YoY

Navidea Biopharmaceutical (AMEX:NAVB) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.11) by 27.27 percent. This is a 38.46 percent increase over losses of $(0.13) per share from the same period last year. The company reported $96.00 thousand in sales this quarter. This is a 64.23 percent decrease over sales of $268.39 thousand the same period last year.